Can a simple infusion shield kidneys during heart surgery?
NCT ID NCT06168799
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a drug called ilofotase alfa can prevent kidney damage in people undergoing open heart surgery. 271 patients received either the drug or a placebo before and after surgery. The goal was to see if the drug could keep kidney function stable and reduce serious kidney events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ilofotase alfa
- What this could lead to
- If it works, this could provide a way to protect kidneys during heart surgery, reducing the risk of long-term kidney problems.
- What could go wrong
- This is a Phase 2 trial with only 271 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPEN HEART SURGERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research site
Munich, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cooling helmet may shield brain from Post-Surgery mental decline
- New study tests gentler anesthesia for heart surgery patients
- Heart drug showdown: which works better during bypass surgery?
- New chest tube method may cut complications after heart surgery
- Could less protamine be safer for heart surgery patients?
- Which blood pressure monitor is best for heart surgery patients? study aims to find out.